These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25224613)

  • 1. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa.
    Corneli AL; McKenna K; Headley J; Ahmed K; Odhiambo J; Skhosana J; Wang M; Agot K;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19152. PubMed ID: 25224613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa.
    Headley J; Lemons A; Corneli A; Agot K; Ahmed K; Wang M; Odhiambo J; Skhosana J; Tharaldson J; Van Damme L; MacQueen K;
    PLoS One; 2014; 9(9):e106410. PubMed ID: 25229403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
    Corneli AL; McKenna K; Perry B; Ahmed K; Agot K; Malamatsho F; Skhosana J; Odhiambo J; Van Damme L
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):578-84. PubMed ID: 25761233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.
    Corneli A; Perry B; McKenna K; Agot K; Ahmed K; Taylor J; Malamatsho F; Odhiambo J; Skhosana J; Van Damme L
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):452-61. PubMed ID: 26536315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.
    Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G; Corneli A
    Cult Health Sex; 2016 Sep; 18(9):1081-91. PubMed ID: 27093238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa.
    Corneli A; Namey E; Ahmed K; Agot K; Skhosana J; Odhiambo J; Guest G
    AIDS Patient Care STDS; 2015 Sep; 29(9):503-9. PubMed ID: 26196411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
    Corneli A; Wang M; Agot K; Ahmed K; Lombaard J; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):555-63. PubMed ID: 25393942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
    Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
    BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
    Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
    PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
    Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
    Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Widow cleansing and inheritance among the Luo in Kenya: the need for additional women-centred HIV prevention options.
    Perry B; Oluoch L; Agot K; Taylor J; Onyango J; Ouma L; Otieno C; Wong C; Corneli A
    J Int AIDS Soc; 2014; 17(1):19010. PubMed ID: 24973041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP.
    Corneli A; Field S; Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G
    PLoS One; 2015; 10(6):e0129177. PubMed ID: 26056842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    Kimani M; van der Elst EM; Chirro O; Wahome E; Ibrahim F; Mukuria N; de Wit TFR; Graham SM; Operario D; Sanders EJ
    PLoS One; 2021; 16(1):e0244226. PubMed ID: 33465090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
    J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
    Agot K; Taylor D; Corneli AL; Wang M; Ambia J; Kashuba AD; Parker C; Lemons A; Malahleha M; Lombaard J; Van Damme L
    AIDS Behav; 2015 May; 19(5):743-51. PubMed ID: 25100053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.